PSNL News and Press, Personalis Inc. From 10/19/22

Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...

Personalis, Inc. (Nasdaq: PSNL) has joined with Duke University and Olink Proteomics AB to form a research collaboration to study the effects of immunotherapy on advanced gastroesophageal cancer. Specifically, the collaboration will focus on identifying composite biomarkers—those...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Morgan Stanley 20 th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 1:30 p.m. Eastern Time in New York, NY. About Pers...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it has filed an amended complaint against Foresight Diagnostics. The amended complaint asserts a newly-issued patent in Personalis’ growing intellectual property portfolio relating to detec...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cathie Wood’s exchange-traded funds (ETFs) received a breath of fresh air this week. The ARK Innovation ETF (NYSEMKT: ARKK ) ended the period up over 12%. Wood did admit that she believes the U.S. is current...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 7 th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Tuesday, August 16, 2022. About Personalis Personalis, Inc...

Personalis, Inc. (PSNL) Q2 2022 Earnings Conference Call August 03, 2022 05:00 PM ET Company Participants Caroline Corner - Investor Relations John West - President & Chief Executive Officer Aaron Tachibana - Chief Financial Officer Conference Call Part...

Personalis press release ( NASDAQ: PSNL ): Q2 GAAP EPS of -$0.60 (vs. -$0.34 Y/Y) beats by $0.03 . Revenue of $18.2M (-16.0% Y/Y) beats by $2.69M . FY22 revenue outlook is between $62.0M and $67.0M (vs. consensus of $64.54M). For further details see: ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2022. Second Quarter and Recent Highlights Reported quarterly revenue of $18.2 million in the second quarter of 202...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it filed a lawsuit against Foresight Diagnostics Inc. for infringement of Personalis’ U.S. Patent Nos. 10,450,611, 11,299,783, and 11,384,394. These patents are part of Personalis ...